Amino acids and mTORC1: From lysosomes to disease

Trends in Molecular Medicine

Volumn 18, Issue 9, 2012, Pages 524-533

  Efeyan, Alejo ^a,b,c   Zoncu, Roberto ^a,b,c   Sabatini, David M ^a,b,c  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATASE; ADENYLATE KINASE; AMINO ACID; DNA; GROWTH FACTOR; GUANOSINE TRIPHOSPHATASE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; RAS PROTEIN; TRANSFER RNA;

AGING; AUTOPHAGY; BANNAYAN RILEY RUVALCABA SYNDROME; BENIGN TUMOR; CANCER SUSCEPTIBILITY; CATABOLISM; CELL GROWTH; CELL METABOLISM; CELL ORGANELLE; CELL VIABILITY; COWDEN SYNDROME; DEGENERATIVE DISEASE; DIABETES MELLITUS; DNA DAMAGE; ENZYME ACTIVITY; GENE MUTATION; GROWTH REGULATION; HEMANGIOMA; HUMAN; HYPOGLYCEMIA; HYPOXIA; KIDNEY CARCINOMA; LIPOGENESIS; LIPOMA; LYSOSOME; MULTIPLE CANCER; NEOPLASM; NEUROFIBROMA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ONCOGENE; PANCREAS TUMOR; PATHOGENESIS; PEUTZ JEGHERS SYNDROME; PHEOCHROMOCYTOMA; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; RIBOSOME; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SYNDROME; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

AMINO ACIDS; DIABETES MELLITUS; HUMANS; LYSOSOMES; MULTIPROTEIN COMPLEXES; NEOPLASMS; NEURODEGENERATIVE DISEASES; TOR SERINE-THREONINE KINASES;

EID: 84865592978     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.05.007     Document Type: Review

References (111)

1. Rabinowitz J.D., White E. Autophagy and metabolism. Science 2010, 330:1344-1348.
2. Zoncu R., et al. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2010, 12:21-35.
3. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
4. Fonseca B.D., et al. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J. Biol. Chem. 2007, 282:24514-24524.
5. Oshiro N., et al. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J. Biol. Chem. 2007, 282:20329-20339.
6. Sancak Y., et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 2007, 25:903-915.
7. Vander Haar E., et al. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 2007, 9:316-323.
8. Xiao B., et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature 2007, 449:496-500.
9. Xiao B., et al. Structure of mammalian AMPK and its regulation by ADP. Nature 2011, 472:230-233.
10. Inoki K., et al. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
11. Shaw R.J., et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:3329-3335.
12. Gwinn D.M., et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30:214-226.
13. Feng Z., et al. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 2007, 67:3043-3053.
14. Jones R.G., et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18:283-293.
15. Brugarolas J., et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004, 18:2893-2904.
16. Gardina P.J., Manson M.D. Attractant signaling by an aspartate chemoreceptor dimer with a single cytoplasmic domain. Science 1996, 274:425-426.
17. Levdikov V.M., et al. The structure of CodY, a GTP- and isoleucine-responsive regulator of stationary phase and virulence in gram-positive bacteria. J. Biol. Chem. 2006, 281:11366-11373.
18. Dong J., et al. Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. Mol. Cell 2000, 6:269-279.
19. Hinnebusch A.G. Translational regulation of GCN4 and the general amino acid control of yeast. Annu. Rev. Microbiol. 2005, 59:407-450.
20. Said A.K., Hegsted D.M. Response of adult rats to low dietary levels of essential amino acids. J. Nutr. 1970, 100:1363-1375.
21. Kroemer G., et al. Autophagy and the integrated stress response. Mol. Cell 2010, 40:280-293.
22. Long X., et al. Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J. Biol. Chem. 2005, 280:23433-23436.
23. Hara K., et al. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem. 1998, 273:14484-14494.
24. Wang X., et al. Amino acid availability regulates p70 S6 kinase and multiple translation factors. Biochem. J. 1998, 334:261-267.
25. Kim E., et al. Regulation of TORC1 by Rag GTPases in nutrient response. Nat. Cell Biol. 2008, 10:935-945.
26. Sancak Y., et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008, 320:1496-1501.
27. Sekiguchi T., et al. Novel G proteins, Rag C and Rag D, interact with GTP-binding proteins, Rag A and Rag B. J. Biol. Chem. 2001, 276:7246-7257.
28. Hirose E., et al. RagA is a functional homologue of S. cerevisiae Gtr1p involved in the Ran/Gsp1-GTPase pathway. J. Cell Sci. 1998, 111:11-21.
29. Korolchuk V.I., et al. Lysosomal positioning coordinates cellular nutrient responses. Nat. Cell Biol. 2011, 13:453-460.
30. Flinn R.J., et al. The late endosome is essential for mTORC1 signaling. Mol. Biol. Cell 2010, 21:833-841.
31. Yoon M.S., et al. Class III PI-3-kinase activates phospholipase D in an amino acid-sensing mTORC1 pathway. J. Cell Biol. 2011, 195:435-447.
32. Kalender A., et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010, 11:390-401.
33. Narita M., et al. Spatial coupling of mTOR and autophagy augments secretory phenotypes. Science 2011, 332:966-970.
34. Sancak Y., et al. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010, 141:290-303.
35. Zoncu R., et al. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H-ATPase. Science 2011, 334:678-683.
36. Puria R., et al. Nuclear translocation of Gln3 in response to nutrient signals requires Golgi-to-endosome trafficking in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7194-7199.
37. Zurita-Martinez S.A., et al. Efficient Tor signaling requires a functional class C Vps protein complex in Saccharomyces cerevisiae. Genetics 2007, 176:2139-2150.
38. Nobukuni T., et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:14238-14243.
39. Wedaman K.P., et al. Tor kinases are in distinct membrane-associated protein complexes in Saccharomyces cerevisiae. Mol. Biol. Cell 2003, 14:1204-1220.
40. Sturgill T.W., et al. TOR1 and TOR2 have distinct locations in live cells. Eukaryot. Cell 2008, 7:1819-1830.
41. Berchtold D., Walther T.C. TORC2 plasma membrane localization is essential for cell viability and restricted to a distinct domain. Mol. Biol. Cell 2009, 20:1565-1575.
42. Bohn G., et al. A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14. Nat. Med. 2007, 13:38-45.
43. Bun-Ya M., et al. Putative GTP-binding protein, Gtr1, associated with the function of the Pho84 inorganic phosphate transporter in Saccharomyces cerevisiae. Mol. Cell. Biol. 1992, 12:2958-2966.
44. Gao M., Kaiser C.A. A conserved GTPase-containing complex is required for intracellular sorting of the general amino-acid permease in yeast. Nat. Cell Biol. 2006, 8:657-667.
45. Binda M., et al. The Vam6 GEF controls TORC1 by activating the EGO complex. Mol. Cell 2009, 35:563-573.
46. Kurzbauer R., et al. Crystal structure of the p14/MP1 scaffolding complex: how a twin couple attaches mitogen-activated protein kinase signaling to late endosomes. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10984-10989.
47. Kogan K., et al. Structural conservation of components in the amino acid sensing branch of the TOR pathway in yeast and mammals. J. Mol. Biol. 2010, 402:388-398.
48. Gong R., et al. Crystal structure of the Gtr1p-Gtr2p complex reveals new insights into the amino acid-induced TORC1 activation. Genes Dev. 2011, 25:1668-1673.
49. Buerger C., et al. Localization of Rheb to the endomembrane is critical for its signaling function. Biochem. Biophys. Res. Commun. 2006, 344:869-880.
50. Saito K., et al. Novel role of the small GTPase Rheb: its implication in endocytic pathway independent of the activation of mammalian target of rapamycin. J. Biochem. 2005, 137:423-430.
51. Klionsky D.J., et al. The fungal vacuole: composition, function, and biogenesis. Microbiol. Rev. 1990, 54:266-292.
52. Kitamoto K., et al. Dynamic aspects of vacuolar and cytosolic amino acid pools of Saccharomyces cerevisiae. J. Bacteriol. 1988, 170:2683-2686.
53. Harms E., et al. Lysosomal pool of free-amino acids. Biochem. Biophys. Res. Commun. 1981, 99:830-836.
54. Yu L., et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 2010, 465:942-946.
55. Li S.C., Kane P.M. The yeast lysosome-like vacuole: endpoint and crossroads. Biochim. Biophys. Acta 2009, 1793:650-663.
56. Russnak R., et al. A family of yeast proteins mediating bidirectional vacuolar amino acid transport. J. Biol. Chem. 2001, 276:23849-23857.
57. Heublein S., et al. Proton-assisted amino-acid transporters are conserved regulators of proliferation and amino-acid-dependent mTORC1 activation. Oncogene 2010, 29:4068-4079.
58. Ruivo R., et al. Mechanism of proton/substrate coupling in the heptahelical lysosomal transporter cystinosin. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E210-E217.
59. Sagne C., et al. Identification and characterization of a lysosomal transporter for small neutral amino acids. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:7206-7211.
60. Bonfils G., et al. Leucyl-tRNA synthetase controls TORC1 via the EGO complex. Mol. Cell 2012, 46:105-110.
61. Han J.M., et al. Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. Cell 2012, 149:410-424.
62. Hosokawa N., et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol. Biol. Cell 2009, 20:1981-1991.
63. Kim J., et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011, 13:132-141.
64. Dubouloz F., et al. The TOR and EGO protein complexes orchestrate microautophagy in yeast. Mol. Cell 2005, 19:15-26.
65. Sardiello M., et al. A gene network regulating lysosomal biogenesis and function. Science 2009, 325:473-477.
66. Settembre C., et al. TFEB links autophagy to lysosomal biogenesis. Science 2011, 332:1429-1433.
67. Martina J.A., et al. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy 2012, 8:903-914.
68. Settembre C., et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012, 31:1095-1108.
69. Duvel K., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39:171-183.
70. Pena-Llopis S., et al. Regulation of TFEB and V-ATPases by mTORC1. EMBO J. 2011, 30:3242-3258.
71. Newgard C.B., et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009, 9:311-326.
72. Khamzina L., et al. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 2005, 146:1473-1481.
73. O'Reilly K.E., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
74. Um S.H., et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004, 431:200-205.
75. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
76. Laplante M., Sabatini D.M. An emerging role of mTOR in lipid biosynthesis. Curr. Biol. 2009, 19:R1046-R1052.
77. Wendel H.G., et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004, 428:332-337.
78. Wendel H.G., et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007, 21:3232-3237.
79. Noda T., Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J. Biol. Chem. 1998, 273:3963-3966.
80. Choo A.Y., et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:17414-17419.
81. Thoreen C.C., et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009, 284:8023-8032.
82. Guertin D.A., et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009, 15:148-159.
83. Chresta C.M., et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010, 70:288-298.
84. Feldman M.E., et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 7:e38.
85. Garcia-Martinez J.M., et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 2009, 421:29-42.
86. Yu K., et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009, 69:6232-6240.
87. European Chromosome 16 Tuberous Sclerosis Consortium Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993, 75:1305-1315.
88. van Slegtenhorst M., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277:805-808.
89. Hemminki A., et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998, 391:184-187.
90. Orlova K.A., et al. STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice. J. Clin. Invest. 2010, 120:1591-1602.
91. Xu G.F., et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990, 62:599-608.
92. Trofatter J.A., et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993, 75:826.
93. Latif F., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320.
94. Liaw D., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 1997, 16:64-67.
95. Zhou X., et al. Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 2001, 358:210-211.
96. Marsh D.J., et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat. Genet. 1997, 16:333-334.
97. Orloff M.S., Eng C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 2008, 27:5387-5397.
98. Lindhurst M.J., et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N. Engl. J. Med. 2011, 365:611-619.
99. Hussain K., et al. An activating mutation of AKT2 and human hypoglycemia. Science 2011, 334:474.
100. Gerlinger M., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
101. Sato T., et al. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 2010, 29:2746-2752.
102. Hudes G., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007, 356:2271-2281.
103. Bissler J.J., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 2008, 358:140-151.
104. Davies D.M., et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N. Engl. J. Med. 2008, 358:200-203.
105. Franz D.N., et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 2006, 59:490-498.
106. Miller R.A., et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J. Gerontol. A: Biol. Sci. Med. Sci. 2011, 66:191-201.
107. Harrison D.E., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
108. Demontis F., Perrimon N. FOXO/4E-BP signaling in Drosophila muscles regulates organism-wide proteostasis during aging. Cell 2010, 143:813-825.
109. Rubinsztein D.C., et al. Autophagy and aging. Cell 2011, 146:682-695.
110. Menzies F.M., et al. Protein misfolding disorders and macroautophagy. Curr. Opin. Cell Biol. 2011, 23:190-197.
111. Ravikumar B., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36:585-595.